Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial

• Published in: Current Alzheimer research Vol. 5; no. 1; p. 73
• Main Authors: Aisen, Paul S, Thal, Leon J, Ferris, Steven H, Assaid, Christopher, Nessly, Michael L, Giuliani, Michael J, Lines, Christopher R, Norman, Barbara A, Potter, William Z
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.02.2008
• Subjects: Alzheimer Disease - diagnosis; Alzheimer Disease - etiology; Alzheimer Disease - prevention & control; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Cognition Disorders - complications; Cognition Disorders - drug therapy; Cyclooxygenase 2 Inhibitors - adverse effects; Cyclooxygenase 2 Inhibitors - therapeutic use; Disease Progression; Double-Blind Method; Humans; Lactones - adverse effects; Lactones - therapeutic use; Proportional Hazards Models; Risk Assessment; Sulfones - adverse effects; Sulfones - therapeutic use; Treatment Failure

A recent clinical trial in patients with Mild Cognitive Impairment (MCI) found an increased rate of possible or probable Alzheimer's disease (AD) diagnoses in patients assigned to rofecoxib compared to placebo. This unexpected finding was difficult to interpret due to methodological issues and...